Galapagos cleans closet of another 4 programs to make room for CAR-T ambitions Amgen takes BiTEs out of pipeline, dropping BCMA, PSMA assets in light of data and competition Akebia’s anemia drug faces further setback after just missing in a COVID-19 trial ‘A negative trial, not a failed trial’: Neurocrine axes in-licensed tremor program on phase 2 data Merck plans to count coughs and months until gefapixant is back in FDA hands More than a year into a full rebuild, Voyager is casting its clinical sails towards the central nervous system Pieris trims fat with phase 2 cancer drug culls to focus on AstraZeneca asthma collab 'The Top Line' podcast: Why early pandemic meds are throwing in the towel, how companies' pipelines have changed this earnings season, plus more Looking east, Sanofi pens 'pioneering' cancer drug partnership with China's Innovent A change of heart: Individual genetic factors could lead to customized cardiac therapies New 'off-the-shelf' stem cell CAR-T to be the basis of company born out of Boston Children’s Hospital and ElevateBio Engineered native gut bacteria shows promise to treat diabetes Chutes & Ladders—Astellas shakes up leadership with two new C-suite execs Fierce Pharma Asia—Sanofi's Innovent tie-up; Astellas' new medical chief; AbbVie's Sosei neurological pact Featured Story | By James Waldron You’d be forgiven for thinking that Galapagos had already trimmed all the fat it could off its pipeline, but the Belgian biotech has managed to find another four early-stage programs worthy of being culled in favor of its CAR-T strategy. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Amgen is bowing out of the congested BCMA race. With a who’s who of drug developers going after the multiple myeloma target, the big biotech has decided to stop work on its bispecific contender as part of a cull that also saw it pick between its two PSMA prospects. read more By James Waldron Akebia’s ambitions for its drug vadadustat has gotten knocked back once again. Less than five months after the FDA dashed the biotech's hopes to market the med for anemia, the therapy has failed to scrape through in a trial of COVID-19 patients with acute respiratory distress syndrome. read more By Nick Paul Taylor Two years after licensing the asset for $45 million upfront, Neurocrine Biosciences has pulled the plug on the development of NBI-827104 in essential tremor after the failure of a phase 2a clinical trial to make the case for further investment. read more By Annalee Armstrong Merck & Co. is going to be counting coughs and months until the P2X3 receptor antagonist medicine gefapixant is back before regulators. read more By Max Bayer More than a year in a full rebuild, Voyager Therapeutics says it has set its sights on the central nervous system as clinical route for its pipeline. The company's top-3 assets are aimed at Alzheimer's, Parkinson's and ALS, respectively. read more By Gabrielle Masson Pieris Pharmaceuticals is trimming the fat, putting its lead immuno-oncology asset on the chopping block to make more room for its AstraZeneca partnership. With the readout AstraZeneca-partnered phase 2 asthma drug now delayed to next year, Pieris has decided to cut it's only clinical-stage independent asset. read more By Teresa Carey This week on "The Top Line," we explore why many early pandemic therapeutics are now throwing in the towel. We also chat about earnings season, and how biotechs' pipelines have changed, even the stuff that companies are less keen to talk about. read more By James Waldron When it comes to global market expansion, many Big Pharmas have their eye on China—and clearly Sanofi is no exception. The French drugmaker has signed a cancer-focused deal with Suzhou-based Innovent, focused on developing and rolling out two of Sanofi’s oncology assets. read more By Gabrielle Masson New research indicates that different individual genetic factors could lead to differing pathways to heart failure, a discovery that paves the way for potential customizable therapies. read more By Max Bayer ElevateBio and Boston Children's Hospital unveiled the first spinoff company from their collaboration announced more than a year ago. The unnamed company will be based on new research showing how a new stem cell-based CAR-T could be effective at killing off tumors. read more By Angus Liu Past research has faced challenges using bacteria cultured in the lab as therapeutics. Now scientists at the University of California, San Diego, have found that native E. coli could be genetically modified to treat chronic disease in the host. read more By Gabrielle Masson,Max Bayer Astellas replaces two outgoing executives, including CMO Zeiher. Nektar's former commercial chief Northcott finds a new gig at Arvinas. Wegner resigns after 10 years at Evaxion. read more By Angus Liu Sanofi has formed an oncology alliance with Eli Lilly's PD-1 partner, Innovent Biologics. Astellas named former AstraZeneca oncology exec Tadaaki Taniguchi as its new chief medical officer. AbbVie has tapped Sosei Heptares to develop drugs against neurological disorders. And more. read more Resources Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Speid & Associates, Inc. The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Nexelis Discover Nexelis’ first-hand perspective on how to develop innovative, agile solutions in vaccine efficacy testing in this exclusive e-book. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Free Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ | 